54 related articles for article (PubMed ID: 29989301)
21. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
Liebenstein TK; Widmer KM; Fallon MJ
J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
[TBL] [Abstract][Full Text] [Related]
22. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
[TBL] [Abstract][Full Text] [Related]
23. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
24. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
[TBL] [Abstract][Full Text] [Related]
26. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
[TBL] [Abstract][Full Text] [Related]
27. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
28. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
29. Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.
Stemler J; Koehler P; Maurer C; Müller C; Cornely OA
Ann Hematol; 2020 Jul; 99(7):1429-1440. PubMed ID: 32514626
[TBL] [Abstract][Full Text] [Related]
30. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.
Chen L; Wang Y; Zhang T; Li Y; Meng T; Liu L; Hao R; Dong Y
BMC Infect Dis; 2018 Apr; 18(1):155. PubMed ID: 29609553
[TBL] [Abstract][Full Text] [Related]
31. Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.
Guarascio AJ; Slain D
Pharmacotherapy; 2015 Feb; 35(2):208-19. PubMed ID: 25644669
[TBL] [Abstract][Full Text] [Related]
32. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts.
Lyseng-Williamson KA
Pharmacoeconomics; 2011 Mar; 29(3):251-68. PubMed ID: 21309616
[TBL] [Abstract][Full Text] [Related]
33. Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.
Frampton JE; Scott LJ
Drugs; 2008; 68(7):993-1016. PubMed ID: 18457464
[TBL] [Abstract][Full Text] [Related]
34. The impact of antifungal prophylaxis in patients diagnosed with acute leukemias undergoing induction chemotherapy: a systematic review and meta-analysis.
Soldi LR; Coelho YNB; Paranhos LR; Silva MJB
Clin Exp Med; 2023 Nov; 23(7):3231-3249. PubMed ID: 37058186
[TBL] [Abstract][Full Text] [Related]
35. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.
Maertens JA; Girmenia C; Brüggemann RJ; Duarte RF; Kibbler CC; Ljungman P; Racil Z; Ribaud P; Slavin MA; Cornely OA; Peter Donnelly J; Cordonnier C; ;
J Antimicrob Chemother; 2018 Dec; 73(12):3221-3230. PubMed ID: 30085172
[TBL] [Abstract][Full Text] [Related]
36. Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation.
Van Daele R; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):539-550. PubMed ID: 32478597
[TBL] [Abstract][Full Text] [Related]
37. Breakthrough Hormographiella aspergillata Infection in a Patient with Acute Myeloid Leukemia Receiving Posaconazole Prophylaxis: A Case Report and Review.
Isabel Cristina RS; Diana A; Karen A
Mycopathologia; 2020 Dec; 185(6):1069-1076. PubMed ID: 32880829
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
